carbapenems has been researched along with Candidemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Awaya, Y; Fujii, S; Hadano, Y; Miura, A; Suyama, A; Suzuki, Y; Tomoda, Y | 1 |
| Aslam, S; Kotton, CN; Kumar, D; Logan, C; Mehta, SR | 1 |
| Ben-Ami, R; Bishara, J; Block, C; Chazan, B; Chowers, M; Dan, M; Giladi, M; Kassis, I; Keller, N; Kontoyiannis, DP; Krieger, M; Olshtain-Pops, K; Oren, I; Potasman, I; Shalit, I; Weber, G; Weinberger, M; Wiener-Well, Y; Zimhony, O | 1 |
1 review(s) available for carbapenems and Candidemia
| Article | Year |
|---|---|
Impact of the antimicrobial stewardship program on hospital-acquired candidemia.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Candidemia; Carbapenems; Hospitals; Humans; Retrospective Studies | 2022 |
2 other study(ies) available for carbapenems and Candidemia
| Article | Year |
|---|---|
Use of organs from donors with bloodstream infection, pneumonia, and influenza: Results of a survey of infectious diseases practitioners.
Topics: Anti-Bacterial Agents; Bacteremia; Bacteria; Candidemia; Carbapenems; Clinical Decision-Making; Cross Infection; Donor Selection; Drug Resistance, Bacterial; Humans; Influenza, Human; Pneumonia; Practice Guidelines as Topic; Surveys and Questionnaires; Tissue Donors; Transplants | 2017 |
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Candida glabrata; Candidemia; Candidiasis; Carbapenems; Clindamycin; Coinfection; Colistin; Drug Resistance, Fungal; Female; Fluconazole; Humans; Israel; Microbial Sensitivity Tests; Middle Aged; Odds Ratio; Prospective Studies; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |